MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2022 International Congress

    Effect of CDNF in a novel combination stressor model of Parkinson’s disease

    A. Singh, A. Panhelainen, M. Voutilainen (Helsinki, Finland)

    Objective: In this study, our first aim was to develop a model for Parkinson's disease (PD) that would exhibit the alpha-synuclein (αSyn) aggregation pathology and…
  • 2022 International Congress

    Effects of a novel neurotrophic compound in an animal model of Parkinson’s disease

    T. Viljakainen, M. Voutilainen (Helsinki, Finland)

    Objective: Investigate the neuroprotective effect of a novel compound in an animal model of Parkinson’s disease. Background: Cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived…
  • 2022 International Congress

    Clove mediated Rescue in Parkinson’s Disease involves modulation of p53 and Sestrin2 in SHSY5Y cell line model

    N. Rai, S. Dey (Udaipur, India)

    Objective: The study analyzed the neuroprotective effect of ethanolic extract of clove against Parkinson’s disease (PD) type toxicity in SHSY5Y cell line model and interrogation…
  • 2022 International Congress

    Phase 2 study evaluating safety, PK/PD, biomarkers, and efficacy of ANX005 in patients with Huntington’s disease (HD)

    R. Kumar, D. Claassen, A. Mongan, A. Grover, B. Hoehn, P. Lin, R. Arnold, E. Cahir-Mcfarland, T. Yednock, S. Keswani (Englewood, USA)

    Objective: To assess the safety, PK/PD, exploratory biomarkers, and efficacy of ANX005 in patients with, or at risk for, manifest HD. Background: Increased complement activation…
  • 2022 International Congress

    Pharmacological activation of Rev-erbα Provides Neuroprotection against Parkinson’s Disease

    L. Kou (Wuhan, China)

    Objective: In this study, we investigated the effects of SR9009, a Rev-ERB agonist, on the dopaminergic system in the MPTP model of PD. Background: Circadian…
  • 2022 International Congress

    Neuroprotective effect of Boswellia dalzielii extracts in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease

    GL. Ndji Otto, H. Adjia, JP. Mingoas Kilekoung (Bertoua, Cameroon)

    Objective: To evaluate the possible protective effects of Boswellia dalzielii in animal model of Parkinson Disease (PD) induced by 6-hydroxydopamine (6-OHDA) injection in the striatum…
  • 2022 International Congress

    Protective effects of Hibiscus sabdariffa extracts in 6-hydroxydopamine-lesioned parkinsonism.

    A. Hamadjida, G. Ndji Otto, MK. Mingoas Kilekoung (bertoua, Cameroon)

    Objective: The therapeutic effects of Hibiscus sabdariffa (HS) were investigated in parkinsonism rats induced by 6-hydroxydopamine (6-OHDA). Background: The oxidative stress is an important component…
  • 2022 International Congress

    ADS024 attenuates striatal dopamine loss and restores movement in animal models of Parkinson’s disease

    L. Chesnel, S. Acton (Concord, USA)

    Objective: To evaluate the effect of ADS024, an oral single strain live biotherapeutic product (SS-LBP), on the pathophysiology of MPTP-induced Parkinson’s Disease (PD) phenotypes in…
  • 2022 International Congress

    A role of β2-adrenoreceptor agonist related to the development of Parkinson’s disease

    WW. Lee (Seoul, Republic of Korea)

    Objective: To explore β2AR agonist’s effect on PD development with controlling for smoking. Background: Several studies have suggested the potential protective role of β2-adrenoreceptor agonist (β2AR…
  • MDS Virtual Congress 2021

    Tinospora Cordifolia protects against Rotenone induced degeneration of dopaminergic neurons in mouse model of Parkinson’s disease

    S. Singh, H. Birla (Varanasi, India)

    Objective: To explore the neuroprotective mechanisms of T. cordifolia ethanolic extract against Rotenone (ROT)-intoxicated mouse model through proteomics approach. Background: The death of dopaminergic (DAergic)…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley